Jonathan Zalevsky - Net Worth and Insider Trading

Jonathan Zalevsky Net Worth

The estimated net worth of Jonathan Zalevsky is at least $217,570 dollars as of 2025-05-06. Jonathan Zalevsky is the Chief R&D Officer of Nektar Therapeutics and owns about 316,604 shares of Nektar Therapeutics (NKTR) stock worth over $217,570. Details can be seen in Jonathan Zalevsky's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jonathan Zalevsky has not made any transactions after 2025-02-19 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data
Unlimited Filters in All-in-One Stock Screener
Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Quick Customer Support
And Much More...

Transaction Summary of Jonathan Zalevsky

To

Jonathan Zalevsky Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jonathan Zalevsky owns 1 companies in total, including Nektar Therapeutics (NKTR) .

Click here to see the complete history of Jonathan Zalevsky’s form 4 insider trades.

Insider Ownership Summary of Jonathan Zalevsky

Ticker Company Transaction Date Type of Owner
NKTR Nektar Therapeutics 2025-02-19 Chief R&D Officer

Jonathan Zalevsky Latest Holdings Summary

Jonathan Zalevsky currently owns a total of 1 stock. Jonathan Zalevsky owns 316,604 shares of Nektar Therapeutics (NKTR) as of February 19, 2025, with a value of $217,570.

Latest Holdings of Jonathan Zalevsky

Ticker Company Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
NKTR Nektar Therapeutics 2025-02-19 316,604 0.69 217,570

Holding Weightings of Jonathan Zalevsky


Jonathan Zalevsky Form 4 Trading Tracker

According to the SEC Form 4 filings, Jonathan Zalevsky has made a total of 23 transactions in Nektar Therapeutics (NKTR) over the past 5 years, including 0 buys and 23 sells. The most-recent trade in Nektar Therapeutics is the sale of 10,300 shares on February 19, 2025, which brought Jonathan Zalevsky around $10,403.

Insider Trading History of Jonathan Zalevsky

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jonathan Zalevsky Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Jonathan Zalevsky Ownership Network

Ownership Network List of Jonathan Zalevsky

No Data

Ownership Network Relation of Jonathan Zalevsky

Insider Network Chart

Jonathan Zalevsky's Compensation Overview

Company Year Salary($) Bonus($) Stock Awards($) Option Awards($) Equity Awards($) Non-Equity Incentive Plan($) All Other Compensation($) Change in Pension and Deferred Comp($) Total($)
Nektar Therapeutics 2023 703,490 N/A N/A 178,300 N/A 400,989 490,585 N/A 1,773,364
LIMIT LIMIT LIMIT LIMIT LIMIT LIMIT LIMIT LIMIT LIMIT LIMIT LIMIT
LIMIT LIMIT LIMIT LIMIT LIMIT LIMIT LIMIT LIMIT LIMIT LIMIT LIMIT

Jonathan Zalevsky Owned Company Details

What does Nektar Therapeutics do?

Who are the key executives at Nektar Therapeutics?

Jonathan Zalevsky is the Chief R&D Officer of Nektar Therapeutics. Other key executives at Nektar Therapeutics include SVP & General Counsel Mark Andrew Wilson , director & President & CEO Howard W Robin , and director & Executive Chairman Robert Chess .

Nektar Therapeutics (NKTR) Insider Trades Summary

Over the past 18 months, Jonathan Zalevsky made 7 insider transaction in Nektar Therapeutics (NKTR) with a net sale of 102,081. Other recent insider transactions involving Nektar Therapeutics (NKTR) include a net sale of 243,523 shares made by Howard W Robin , a net sale of 94,105 shares made by Mark Andrew Wilson , and a net sale of 56,000 shares made by .

In summary, during the past 3 months, insiders sold 45,114 shares of Nektar Therapeutics (NKTR) in total and bought 0 shares, with a net sale of 45,114 shares. During the past 18 months, 515,209 shares of Nektar Therapeutics (NKTR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 515,209 shares.

Nektar Therapeutics (NKTR)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Nektar Therapeutics Insider Transactions

No Available Data

Jonathan Zalevsky Mailing Address

Above is the net worth, insider trading, and ownership report for Jonathan Zalevsky. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Jonathan Zalevsky's mailing address is: San Francisco Ca 94158.